Thank you so much for this question. It's an excellent question.
Being able to execute clinical trials is absolutely critical for providing early access to novel therapies for patients in a variety of different disease areas. What is equally important, however, is to ensure that we support the pathway from the discovery of an exciting new and novel therapy to getting it to a clinical trial.
Most of the molecules and products that we're looking at are known as biologics. They can be viruses, they can be antibodies or they can be modified cellular therapies. Building up the regulatory dossier, especially for a first-in-human study, is the key to entry in delivering a clinical trial here in Canada. This is what my organization is involved in. We're supporting that bench-to-bedside translation to really increase the number of clinical trials in Canada and to increase access of those clinical trials to as many cancer patients in Canada as possible.
Ensuring that we have bench-to-bedside translational support that involves the coordination of biomanufacturing and that really enables our companies and our innovators to build up a regulatory dossier so they're able to knock on the door of Health Canada with a clinical trial application is the critical first step and a necessary condition to being able to execute a clinical trial in this country.